This company listing is no longer active
Intelligent Medicine Acquisition Past Earnings Performance
Past criteria checks 1/6
Key information
-23.3%
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Intelligent Medicine Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | 11 | 0 | 0 |
| 30 Sep 22 | 0 | 23 | 1 | 0 |
| 30 Jun 22 | 0 | 22 | 1 | 0 |
| 31 Mar 22 | 0 | 19 | 0 | 0 |
Quality Earnings: IQMD has high quality earnings.
Growing Profit Margin: Insufficient data to determine if IQMD's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if IQMD's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare IQMD's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: IQMD had negative earnings growth (-23.3%) over the past year, making it difficult to compare to the Capital Markets industry average (28.1%).
Return on Equity
High ROE: IQMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.